Vanda Pharmaceuticals Announces The Publication Of Efficacy And Safety Of Iloperidone In Bipolar Mania: A Double-Blind, Placebo-Controlled Study In The Journal Of Clinical Psychiatry; Findings Of Study Have Been Submitted To The U.S. FDA
Portfolio Pulse from Benzinga Newsdesk
Vanda Pharmaceuticals Inc. has published a study on the efficacy and safety of Iloperidone in treating bipolar mania in the Journal of Clinical Psychiatry. The study's results have been submitted to the FDA as part of a supplemental New Drug Application for Fanapt, with a target action date of April 2, 2024, for the FDA's decision.
January 17, 2024 | 8:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vanda Pharmaceuticals' recent publication and FDA submission for Iloperidone could positively influence investor sentiment, potentially impacting VNDA's stock price in anticipation of the FDA's decision.
The publication of positive study results typically generates optimism among investors, especially when it is linked to a potential new treatment indication. The FDA's review process adds a layer of validation and anticipation, which can lead to increased investor interest and potentially a higher stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100